Home Metabolism Isocitrate Dehydrogenase (IDH)

Isocitrate Dehydrogenase (IDH)

Other Metabolism Related Inhibitors

Dehydrogenase Transferase DPP Aminopeptidase Procollagen C Proteinase P450 (e.g. CYP17) Phospholipase (e.g. PLA) Factor Xa PDE DHFR
Cat.No. Product Name Information Product Use Citations Product Validations
S8611 Vorasidenib (AG-881) Vorasidenib (AG-881) is an orally available inhibitor of mutated forms of both isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2).
EBioMedicine, 2024, 102:105090
Cancer Res Commun, 2024, 4(3):876-894
Cancer Discov, 2023, 13(1):170-193
S8205 AG-221 (Enasidenib) Enasidenib (AG-221) is a first-in-class, oral, potent, reversible, selective inhibitor of the IDH2 mutant enzyme.
iScience, 2025, 28(2):111833
iScience, 2024, 27(10):110862
Hematol Oncol, 2024, 42(6):e3316
E7887 Mutant IDH1-IN-1 Mutant IDH1-IN-1 is a mutant-selective IDH1 inhibitor with with IC50s of 4, 42, 80 and 143 nM against mutant IDH1 R132C/R132C, IDH1 R132H/R132H, IDH1 R132H/WT and wild type IDH1, respectively.
S7185 AGI-5198 AGI-5198 (IDH-C35) is the first highly potent and selective inhibitor of IDH1 R132H/R132C mutants with IC50 of 0.07 μM/0.16 μM.
EMBO Mol Med, 2025, 10.1038/s44321-025-00296-2
EBioMedicine, 2024, 102:105090
Cancers -Basel), 2023, 15(19)4772
Verified customer review of AGI-5198
S7241 AGI-6780 AGI-6780 is a potent and selective inhibitor of IDH2 R140Q mutant with IC50 of 23 nM.
Nat Commun, 2025, 16(1):8083
Nat Commun, 2025, 16(1):6913
EMBO Mol Med, 2025, 10.1038/s44321-025-00296-2
Verified customer review of AGI-6780
S8206 AG-120 (Ivosidenib) Ivosidenib (AG-120) is an orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity.
EBioMedicine, 2024, 102:105090
Biomed Pharmacother, 2024, 180:117533
iScience, 2024, 27(10):110862
Verified customer review of AG-120 (Ivosidenib)
S8530 BAY 1436032 BAY-1436032 is a highly selective, potent and orally available inhibitor of mutant Isocitrate Dehydrogenase 1 (mIDH1). It is a double-digit nanomolar and selective pan-inhibitor of the enzymatic activity of various IDH1-R132X mutants in vitro and displays potent inhibition of 2-HG release (nanomolar range) in patient derived and engineered cell lines expressing different IDH1 mutants.
Yonsei University Medical Library, 2022,
Haematologica, 2020, 2 pii: haematol
S8881 DS-1001b (DS 1001) DS-1001b is an oral selective inhibitor of mutant IDH1 R132X with potential antineoplastic activity and is designed to penetrate the blood-brain barrier.
EBioMedicine, 2024, 102:105090
S8949 Olutasidenib Olutasidenib is a potent, orally bioavailable, brain penetrant and selective mutant IDH1 (mIDH1) inhibitor with IC50 of 21.1 nM, 114 nM for IDH1-R132H, IDH1-R132C, respectively.